Peiling Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Peiling Li has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
Yimei Meng
Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China, hrbmush.edu.cn
4 shared publicationsYuhan Wang
Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China
4 shared publicationsHuafeng Ding
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Wannan Medical College Wuhu 241001, Anhui, P. R. China
3 shared publicationsJiayin Gao
Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China
3 shared publicationsYuanyuan Lyu
Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Harbin Medical University Harbin 150086, Heilongjiang, P. R. China
3 shared publicationsChangmin Li
Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China
2 shared publications
Latest Publications
- Open Access
- 4 June 2026
- Published by Elsevier in Translational Oncology
- Vol. 70, 102844
Super-enhancer-driven ITGB2-AS1 promotes ovarian cancer progression by binding to IQGAP1
- 4 June 2026
- Published by Elsevier in Translational Oncology
- Vol. 70, 102844
Open AccessSuper-enhancer-driven ITGB2-AS1 promotes ovarian cancer progression by binding to IQGAP1
- Open Access
- 21 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1)
IPO9 Promotes Ovarian Cancer Progression by Suppressing HMOX1‐Dependent Ferroptosis
Ovarian cancer (OC) poses a significant threat to women’s health, with current treatment strategies remaining suboptimal, necessitating the exploration of novel therapeutic targets and immune microenvironment dynamics. This study integrates multiomics data from TCGA, GEO, and IEU‐Open‐GWAS, employing scRNA‐seq, scPagwas, BayesPrism, and WGCNA to identify key cell subpopulations and genes, followed by functional validation through EdU, colony formation, Transwell assays, and ferroptosis markers (MDA, ROS, and ferrous ions). Results reveal MALAT1 + epithelial cells as a core cell subpopulation in OC, with higher abundance correlating with shorter overall survival, suppressed immune microenvironments, and potential immunotherapy resistance, while their infiltration levels are closely associated with OC immune dynamics and somatic mutations. Further analysis identifies IPO9 as a core gene upregulated in OC, promoting tumor progression by inhibiting HMOX1‐dependent ferroptosis. These findings highlight MALAT1 + epithelial cells as drivers of immune suppression in OC and propose IPO9 as a promising therapeutic target, offering new avenues for immunotherapy development.
- 21 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1)
Open AccessIPO9 Promotes Ovarian Cancer Progression by Suppressing HMOX1‐Dependent Ferroptosis
Ovarian cancer (OC) poses a significant threat to women’s health, with current treatment strategies remaining suboptimal, necessitating the exploration of novel therapeutic targets and immune microenvironment dynamics. This study integrates multiomics data from TCGA, GEO, and IEU‐Open‐GWAS, employing scRNA‐seq, scPagwas, BayesPrism, and WGCNA to identify key cell subpopulations and genes, followed by functional validation through EdU, colony formation, Transwell assays, and ferroptosis markers (MDA, ROS, and ferrous ions). Results reveal MALAT1 + epithelial cells as a core cell subpopulation in OC, with higher abundance correlating with shorter overall survival, suppressed immune microenvironments, and potential immunotherapy resistance, while their infiltration levels are closely associated with OC immune dynamics and somatic mutations. Further analysis identifies IPO9 as a core gene upregulated in OC, promoting tumor progression by inhibiting HMOX1‐dependent ferroptosis. These findings highlight MALAT1 + epithelial cells as drivers of immune suppression in OC and propose IPO9 as a promising therapeutic target, offering new avenues for immunotherapy development.
- 1 January 2026
- Published by e-Century Publishing Corporation in American Journal of Cancer Research
- Vol. 16 (5) , 2100-2101
Hypoxia-induced m6A demethylase ALKBH5 promotes ovarian cancer tumorigenicity by decreasing methylation of the lncRNA RMRP: Am J Cancer Res. 2023; 13(9): 4179-4191
[This corrects the article on p. 4179 in vol. 13, PMID: 37818080.].
- 1 January 2026
- Published by e-Century Publishing Corporation in American Journal of Cancer Research
- Vol. 16 (5) , 2100-2101
Hypoxia-induced m6A demethylase ALKBH5 promotes ovarian cancer tumorigenicity by decreasing methylation of the lncRNA RMRP: Am J Cancer Res. 2023; 13(9): 4179-4191
[This corrects the article on p. 4179 in vol. 13, PMID: 37818080.].
- Open Access
- 29 November 2025
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 19 (1)
M6A modification mediates CACNA1A stability to drive the progression of ovarian cancer by inhibiting ferroptosis
Ovarian cancer is a particularly lethal form of cancer affecting the female reproductive system. Prior research indicates a strong link between RNA epigene
- 29 November 2025
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 19 (1)
Open AccessM6A modification mediates CACNA1A stability to drive the progression of ovarian cancer by inhibiting ferroptosis
Ovarian cancer is a particularly lethal form of cancer affecting the female reproductive system. Prior research indicates a strong link between RNA epigene
- Open Access
- 15 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-15
Assessment of lncRNA biomarkers based on NETs for prognosis and therapeutic response in ovarian cancer
Ovarian cancer (OC) usually progresses rapidly and is associated with high mortality, while a reliable clinical factor for OC patients to predict prognosis is currently lacking. Recently, the pathogenic role of neutrophils releasing neutrophil extracellular traps (NETs) in various cancers including OC has gradually been recognized. The study objective was to determine whether NETs-related biomarkers can be used to accurately predict the prognosis and guide clinical decision-making in OC. In this study, we utilized univariate and multivariate Cox regression to identify key prognostic features and developed a model with six NETs-related lncRNAs, selected via LASSO regression. The model’s predictive capability was assessed through Kaplan–Meier, ROC, and Cox analyses. To understand the model’s mechanisms, we conducted GO term analysis, KEGG pathway enrichment, and GSEA. We also analyzed gene mutation status, tumor mutation load, survival rates, and model correlation. Additionally, we compared immune functions, immune checkpoint expression, and chemotherapy sensitivity between risk groups. Besides, we validated the model’s predictive value using test data and tissues acquired from our institution. Finally, we performed in vitro and in vivo experiments to confirm the expression of model lncRNAs and the cellular level function of GAS5. We developed a model using six NETs-associated lncRNAs: GAS5, GBP1P1, LINC00702, LINC01933, LINC02362, and ZNF687-AS1. The model’s predictive performance, evaluated via ROC curve, was compared with traditional clinicopathological features. GO process analysis highlighted molecular functions related to antigen binding and immune system biological processes. Variations were observed in transcription regulators affecting immune response, inflammation, cytotoxicity, and regulation. We also predicted IC50 values for chemotherapeutic drugs (bexarotene, bicalutamide, embelin, GDC0941, and thapsigargin) in high- and low-risk groups, finding higher IC50 values in low-risk patients. The risk model’s robustness was validated using OC cells, tissues, and clinical datas.
- 15 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-15
Open AccessAssessment of lncRNA biomarkers based on NETs for prognosis and therapeutic response in ovarian cancer
Ovarian cancer (OC) usually progresses rapidly and is associated with high mortality, while a reliable clinical factor for OC patients to predict prognosis is currently lacking. Recently, the pathogenic role of neutrophils releasing neutrophil extracellular traps (NETs) in various cancers including OC has gradually been recognized. The study objective was to determine whether NETs-related biomarkers can be used to accurately predict the prognosis and guide clinical decision-making in OC. In this study, we utilized univariate and multivariate Cox regression to identify key prognostic features and developed a model with six NETs-related lncRNAs, selected via LASSO regression. The model’s predictive capability was assessed through Kaplan–Meier, ROC, and Cox analyses. To understand the model’s mechanisms, we conducted GO term analysis, KEGG pathway enrichment, and GSEA. We also analyzed gene mutation status, tumor mutation load, survival rates, and model correlation. Additionally, we compared immune functions, immune checkpoint expression, and chemotherapy sensitivity between risk groups. Besides, we validated the model’s predictive value using test data and tissues acquired from our institution. Finally, we performed in vitro and in vivo experiments to confirm the expression of model lncRNAs and the cellular level function of GAS5. We developed a model using six NETs-associated lncRNAs: GAS5, GBP1P1, LINC00702, LINC01933, LINC02362, and ZNF687-AS1. The model’s predictive performance, evaluated via ROC curve, was compared with traditional clinicopathological features. GO process analysis highlighted molecular functions related to antigen binding and immune system biological processes. Variations were observed in transcription regulators affecting immune response, inflammation, cytotoxicity, and regulation. We also predicted IC50 values for chemotherapeutic drugs (bexarotene, bicalutamide, embelin, GDC0941, and thapsigargin) in high- and low-risk groups, finding higher IC50 values in low-risk patients. The risk model’s robustness was validated using OC cells, tissues, and clinical datas.
- 4 January 2025
- Published by Elsevier in Experimental Cell Research
- Vol. 445 (1) , 114405
IGSF8 impairs migration and invasion of trophoblast cells and angiogenesis in preeclampsia
- 4 January 2025
- Published by Elsevier in Experimental Cell Research
- Vol. 445 (1) , 114405
IGSF8 impairs migration and invasion of trophoblast cells and angiogenesis in preeclampsia
- Open Access
- 27 November 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-18
METTL2B m3C RNA transferase: oncogenic role in ovarian cancer progression via regulation of the mTOR/AKT pathway and its link to the tumor immune microenvironment
Aberrant expression of N3-methylcytidine methyltransferase 2B (METTL2B) has been observed in various human malignancies, including those of the prostate, liver, breasts, and bladder. However, its role in ovarian cancer (OC) remains largely unexplored. This research preliminarily investigated METTL2B expression in OC and elucidated the associated molecular mechanisms. We utilized three publicly available cancer-related databases (Genotype-Tissue Expression, Gene Expression Omnibus, and The Cancer Genome Atlas) to identify gene signatures in patients with OC and normal individuals with a specific focus on METTL2B. The role of METTL2B in OC was evaluated using patient survival data, and its impact on oncogenic behaviors in both cell and animal models, including growth potential, migration, invasion, and the tumor microenvironment, was examined. This assessment was conducted using bioinformatics tools such as Gene Set Cancer Analysis, GeneMANIA, and Tumor Immune Single-cell Hub 2. Additionally, the association between drug sensitivity and METTL2B expression was analyzed using CellMiner. METTL2B expression was significantly elevated in OC, highlighting its potential clinical value in the diagnosis and prognosis of OC. Patients with lower METTL2B expression exhibited favorable survival. Furthermore, METTL2B knockdown significantly disrupted oncogenic behaviors in OC cell lines by suppressing the mTOR/AKT signaling pathway. Additionally, bioinformatics-based Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses suggested a close correlation between METTL2B and immune responses. Our research confirmed the upregulation of METTL2B in OC, suggesting its oncogenic function. However, METTL2B expression was negatively correlated with the infiltration scores of multiple immune cells, including cytotoxic cells and T cells, indicating its complex role in the tumor immune microenvironment. These findings highlight the significant clinical value of METTL2B in the diagnosis and prognosis of OC.
- 27 November 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-18
Open AccessMETTL2B m3C RNA transferase: oncogenic role in ovarian cancer progression via regulation of the mTOR/AKT pathway and its link to the tumor immune microenvironment
Aberrant expression of N3-methylcytidine methyltransferase 2B (METTL2B) has been observed in various human malignancies, including those of the prostate, liver, breasts, and bladder. However, its role in ovarian cancer (OC) remains largely unexplored. This research preliminarily investigated METTL2B expression in OC and elucidated the associated molecular mechanisms. We utilized three publicly available cancer-related databases (Genotype-Tissue Expression, Gene Expression Omnibus, and The Cancer Genome Atlas) to identify gene signatures in patients with OC and normal individuals with a specific focus on METTL2B. The role of METTL2B in OC was evaluated using patient survival data, and its impact on oncogenic behaviors in both cell and animal models, including growth potential, migration, invasion, and the tumor microenvironment, was examined. This assessment was conducted using bioinformatics tools such as Gene Set Cancer Analysis, GeneMANIA, and Tumor Immune Single-cell Hub 2. Additionally, the association between drug sensitivity and METTL2B expression was analyzed using CellMiner. METTL2B expression was significantly elevated in OC, highlighting its potential clinical value in the diagnosis and prognosis of OC. Patients with lower METTL2B expression exhibited favorable survival. Furthermore, METTL2B knockdown significantly disrupted oncogenic behaviors in OC cell lines by suppressing the mTOR/AKT signaling pathway. Additionally, bioinformatics-based Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses suggested a close correlation between METTL2B and immune responses. Our research confirmed the upregulation of METTL2B in OC, suggesting its oncogenic function. However, METTL2B expression was negatively correlated with the infiltration scores of multiple immune cells, including cytotoxic cells and T cells, indicating its complex role in the tumor immune microenvironment. These findings highlight the significant clinical value of METTL2B in the diagnosis and prognosis of OC.
- 23 July 2024
- Published by Springer Nature in Medical Oncology
- Vol. 41 (8) , 1-10
PARK2 suppresses the proliferation of high-grade serous ovarian carcinoma via inducing the proteasomal degradation of ZNF703
High-grade serous ovarian cancer (HGSC) is an aggressive disease with poor prognosis. The oncoprotein ZNF703 is implicated in driving HGSC pathogenesis, but factors regulating its abundance remain unclear. In this study, we aim to investigate the potential connection between ZNF703 dysregulation and ubiquitin-mediated protein degradation in HGSC. Bioinformatics prediction was performed using BioGRID database. HGSC representative cell lines were utilized for in vitro and in vivo studies. Results showed that ZNF703 protein was stabilized upon proteasome inhibition, suggesting a regulation via ubiquitination. The ubiquitin E3 ligase PARK2 was found to interact with ZNF703 in a dose-dependent manner, promoting its polyubiquitination and subsequent proteasomal degradation. Re-expression of PARK2 in HGSC cells led to reduced ZNF703 levels together with decreased Cyclin D1/E1 abundance and G1 cell cycle arrest. ZNF703 overexpression alone increased S phase cells, Cyclin D1/E1 levels, and xenograft tumor growth, while co-expression with PARK2 mitigated these oncogenic effects. Collectively, our findings identify ZNF703 as a bona fide substrate of PARK2, reveal a tumor suppressive function for PARK2 in attenuating ZNF703-mediated G1/S transition and HGSC growth through instigating its degradation. This study elucidates a pivotal PARK2-ZNF703 axis with therapeutic implications for targeted intervention in HGSC.
- 23 July 2024
- Published by Springer Nature in Medical Oncology
- Vol. 41 (8) , 1-10
PARK2 suppresses the proliferation of high-grade serous ovarian carcinoma via inducing the proteasomal degradation of ZNF703
High-grade serous ovarian cancer (HGSC) is an aggressive disease with poor prognosis. The oncoprotein ZNF703 is implicated in driving HGSC pathogenesis, but factors regulating its abundance remain unclear. In this study, we aim to investigate the potential connection between ZNF703 dysregulation and ubiquitin-mediated protein degradation in HGSC. Bioinformatics prediction was performed using BioGRID database. HGSC representative cell lines were utilized for in vitro and in vivo studies. Results showed that ZNF703 protein was stabilized upon proteasome inhibition, suggesting a regulation via ubiquitination. The ubiquitin E3 ligase PARK2 was found to interact with ZNF703 in a dose-dependent manner, promoting its polyubiquitination and subsequent proteasomal degradation. Re-expression of PARK2 in HGSC cells led to reduced ZNF703 levels together with decreased Cyclin D1/E1 abundance and G1 cell cycle arrest. ZNF703 overexpression alone increased S phase cells, Cyclin D1/E1 levels, and xenograft tumor growth, while co-expression with PARK2 mitigated these oncogenic effects. Collectively, our findings identify ZNF703 as a bona fide substrate of PARK2, reveal a tumor suppressive function for PARK2 in attenuating ZNF703-mediated G1/S transition and HGSC growth through instigating its degradation. This study elucidates a pivotal PARK2-ZNF703 axis with therapeutic implications for targeted intervention in HGSC.
- Open Access
- 30 October 2023
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 11 (10) , e1006
SAMD1 attenuates antiphospholipid syndrome‐induced pregnancy complications
Objective: This study was intended to investigate the effect of SAMD1 on antiphospholipid syndrome (APS)‐induced pregnancy complications in mice.Methods: The mRNA and protein expression of SAMD1 in APS patients and healthy controls was detected by qRT‐PCR and western blot. Anti‐B2GPI and ACA levels were tested by ELISA, MMP‐9, iNOS, ICAM‐1 and MCP‐1 mRNA and protein levels determined by qRT‐PCR and western blot, cellular senescence detected by β‐galactosidase staining, cell proliferation ability detected by CCK‐8 assay, cell viability detected by trypan blue staining, cell mobility detected by Transwell, and cell angiogenesis ability detected by matrigel tube formation assay. An APS pregnant mouse model was constructed, and the embryo absorption rate was calculated.Results: SAMD1 expression was low in serum of APS patients, which was correlated with the history of thrombosis and the number of adverse pregnancies. Anti‐B2GPI and ACA levels were increased in APS. The expressions of MMP‐9, iNOS, ICAM‐1, and MCP‐1 were also significantly upregulated in HUVECs treated with APS serum. APS promoted HUVEC senescence and inhibited cell proliferation, migration and angiogenesis. Overexpression of SAMD1 reversed the above results. Experiments on the APS pregnant mouse model confirmed that overexpression of SAMD1 reduced the rate of fetal loss.Conclusion: SAMD1 may reduce APS‐induced embryo loss by regulating cellular senescence, proliferation, migration, and angiogenesis.
- 30 October 2023
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 11 (10) , e1006
Open AccessSAMD1 attenuates antiphospholipid syndrome‐induced pregnancy complications
Objective: This study was intended to investigate the effect of SAMD1 on antiphospholipid syndrome (APS)‐induced pregnancy complications in mice.Methods: The mRNA and protein expression of SAMD1 in APS patients and healthy controls was detected by qRT‐PCR and western blot. Anti‐B2GPI and ACA levels were tested by ELISA, MMP‐9, iNOS, ICAM‐1 and MCP‐1 mRNA and protein levels determined by qRT‐PCR and western blot, cellular senescence detected by β‐galactosidase staining, cell proliferation ability detected by CCK‐8 assay, cell viability detected by trypan blue staining, cell mobility detected by Transwell, and cell angiogenesis ability detected by matrigel tube formation assay. An APS pregnant mouse model was constructed, and the embryo absorption rate was calculated.Results: SAMD1 expression was low in serum of APS patients, which was correlated with the history of thrombosis and the number of adverse pregnancies. Anti‐B2GPI and ACA levels were increased in APS. The expressions of MMP‐9, iNOS, ICAM‐1, and MCP‐1 were also significantly upregulated in HUVECs treated with APS serum. APS promoted HUVEC senescence and inhibited cell proliferation, migration and angiogenesis. Overexpression of SAMD1 reversed the above results. Experiments on the APS pregnant mouse model confirmed that overexpression of SAMD1 reduced the rate of fetal loss.Conclusion: SAMD1 may reduce APS‐induced embryo loss by regulating cellular senescence, proliferation, migration, and angiogenesis.
- 1 January 2023
- Vol. 13 (9) , 4179-4191
Hypoxia-induced m6A demethylase ALKBH5 promotes ovarian cancer tumorigenicity by decreasing methylation of the lncRNA RMRP
Ovarian cancer is one of the most lethal and drug-resistant gynecological diseases. Among the various post-transcriptional RNA modifications, N6-methyladenosine (m6A) has been implicated in several malignancies, including breast cancer. Recently, the biological significance of long noncoding RNA (lncRNA) methylation has garnered significant attention. The N6-methyladenosine (m6A) demethylase ALKBH5 (Alkylation Repair Homolog Protein 5) has been shown to promote ovarian cancer development by reducing the methylation of the lncRNA RMRP. In this study, we found that a hypoxic microenvironment induces an increase in ALKBH5 expression in ovarian cancer. Both in vitro and in vivo investigations demonstrated that ALKBH5, which is overexpressed in human ovarian cancer, promotes carcinogenesis. Furthermore, using bioinformatics analysis, we predicted interactions between ALKBH5 and lncRNAs, confirming RMRP as a potential binding lncRNA for ALKBH5. ALKBH5 was found to upregulate RMRP expression via demethylation. Knockdown of RMRP in ovarian cancer cell lines led to a decrease in cell growth and migration. Additionally, we demonstrated that the inhibition of ovarian cancer by ALKBH5 knockdown is partially mediated by RMRP suppression. In conclusion, our findings reveal a novel mechanism in which ALKBH5 promotes ovarian cancer by demethylating the lncRNA RMRP, suggesting its potential as a therapeutic target for the disease.
- 1 January 2023
- Vol. 13 (9) , 4179-4191
Hypoxia-induced m6A demethylase ALKBH5 promotes ovarian cancer tumorigenicity by decreasing methylation of the lncRNA RMRP
Ovarian cancer is one of the most lethal and drug-resistant gynecological diseases. Among the various post-transcriptional RNA modifications, N6-methyladenosine (m6A) has been implicated in several malignancies, including breast cancer. Recently, the biological significance of long noncoding RNA (lncRNA) methylation has garnered significant attention. The N6-methyladenosine (m6A) demethylase ALKBH5 (Alkylation Repair Homolog Protein 5) has been shown to promote ovarian cancer development by reducing the methylation of the lncRNA RMRP. In this study, we found that a hypoxic microenvironment induces an increase in ALKBH5 expression in ovarian cancer. Both in vitro and in vivo investigations demonstrated that ALKBH5, which is overexpressed in human ovarian cancer, promotes carcinogenesis. Furthermore, using bioinformatics analysis, we predicted interactions between ALKBH5 and lncRNAs, confirming RMRP as a potential binding lncRNA for ALKBH5. ALKBH5 was found to upregulate RMRP expression via demethylation. Knockdown of RMRP in ovarian cancer cell lines led to a decrease in cell growth and migration. Additionally, we demonstrated that the inhibition of ovarian cancer by ALKBH5 knockdown is partially mediated by RMRP suppression. In conclusion, our findings reveal a novel mechanism in which ALKBH5 promotes ovarian cancer by demethylating the lncRNA RMRP, suggesting its potential as a therapeutic target for the disease.